# Arbutus Biopharma Corporation Common Stock (ABUS)

> Arbutus Biopharma Corporation Common Stock (ABUS) trades at $4.02 (-1.23%) as of 7:39:17 PM EST on Nov 20, 2026, -4.51% over the past month. Market cap is $616.24M, with 9.1 days to cover in short interest.

Canonical: https://massive.com/quote/abus
Data as of: 2026-11-21T00:39:17.734Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$4.02** -0.05 (-1.23%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$3.98** -0.04 (-0.99%)
As of 7:39:17 PM EST on Nov 20, 2026 · After hours

## Stock performance

How Arbutus Biopharma Corporation Common Stock (ABUS) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -1.23% |
| 1W | -1.71% |
| 1M | -4.51% |
| YTD | -16.42% |
| 1Y | -5.85% |
| 52-wk range | $3.50 – $5.45 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for ABUS: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $3.97 – $4.09 |
| Open | $4.01 |
| Prev close | $4.07 |
| Volume | 2.99M |
| Market cap | $616.24M |
| Shares out | 153.29M |

## Valuation and profitability ratios

Valuation and profitability ratios for Arbutus Biopharma Corporation Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | 2.80 |
| P/S | 3.40 |
| P/B | 7.19 |
| P/FCF | 2.79 |
| ROE | 256.4% |
| ROA | 64.7% |
| Debt/Equity | 0.03 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[Arbutus Biopharma Corporation Common Stock (ABUS) insider trading](https://massive.com/quote/abus/insider-trading.md): open-market Form 4 buys and sells by Arbutus Biopharma Corporation Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Arbutus Biopharma Corporation Common Stock has disclosed to the SEC on Form 8-K.

- Nov 12, 2026 · Investor presentation
  “On November 12, 2026, Arbutus Biopharma Corporation posted an updated corporate presentation on its website at www.arbutusbio.com. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.”
- Nov 10, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 10, 2026, Arbutus Biopharma Corporation ("Arbutus") issued a press release announcing its financial results for the third quarter ended September 30, 2026 and certain other information.”
- Oct 22, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “On October 22, 2026, Arbutus Biopharma Corporation (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational New Drug application for AB-101, the Company's oral PD-L1 inhibitor.”
- Aug 21, 2026 · Tender offer
  “On August 21, 2026, Arbutus Biopharma Corporation (the "Company") issued a press release announcing its plans to launch a modified "Dutch auction" tender offer to purchase up to US$230 million in value of its common shares, at a price ranging from US$5.00 to US$5.75.”
- Jul 16, 2026 · Deal termination
  “On July 15, 2026, Arbutus and Genevant entered into a termination agreement (the 'Termination Agreement') filed herewith as Exhibit 10.1 to terminate the RSV Agreement. Pursuant to the Termination Agreement, Genevant will pay Arbutus a termination fee of $1.0 million within ten business days of the date of the Termination Agreement, and all rights or obligations under the RSV Agreement are terminated.”

## ABUS short interest

How heavily ABUS is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 9.1 |
| Short interest | 19.89M |
| Avg volume | 2.18M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## ABUS news

The latest news and headlines about Arbutus Biopharma Corporation Common Stock (ABUS).

- [MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises](https://www.zacks.com/stock/news/3025875/mrna-q3-earnings-beat-on-covid-sales-raises-26-outlook-stock-rises?cid=CS-ZC-FT-analyst_blog|earnings_article-3025875) · Zacks Investment Research · Nov 6, 2026 · positive sentiment
- [9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential](https://www.investing.com/analysis/9-biotech-stocks-trading-far-below-fair-value-with-250-upside-potential-200676103) · Investing.com · Mar 5, 2026 · neutral sentiment
- [Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars](https://www.benzinga.com/news/legal/26/03/51032182/modernas-950-million-settlement-clears-legal-overhang-stock-soars?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Mar 4, 2026 · positive sentiment
- [Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.](https://www.fool.com/investing/2025/02/20/will-moderna-stock-drop-to-25-1-wall-street-analys/?source=iedfolrf0000001) · The Motley Fool · Feb 20, 2025 · negative sentiment
- [Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?](https://www.zacks.com/stock/news/2287612/ultragenyx-rare-moves-78-higher-will-this-strength-last) · Zacks Investment Research · Jun 13, 2024

## About Arbutus Biopharma Corporation Common Stock

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 19 |
| Listed | Jul 26, 2007 |

[Company website](http://www.arbutusbio.com)

## FAQ

### What is the Arbutus Biopharma Corporation Common Stock (ABUS) stock price today?

Arbutus Biopharma Corporation Common Stock (ABUS) is trading at $4.02 (-1.23% on the day) as of 7:39:17 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Arbutus Biopharma Corporation Common Stock?

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a…

### What is the short interest in ABUS?

As of Oct 30, 2026, ABUS has 19.89M shares short and 9.1 days to cover.

### What exchange is ABUS listed on?

Arbutus Biopharma Corporation Common Stock (ABUS) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time ABUS quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ABUS`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Arbutus Biopharma Corporation Common Stock (ABUS) insider trading](https://massive.com/quote/abus/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
